Celldex Therapeutics Inc
CLDX22.010USD
-0.180-0.81%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.46BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Celldex Therapeutics Inc Unternehmen
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Unternehmensinformationen
BörsenkürzelCLDX
Name des UnternehmensCelldex Therapeutics Inc
IPO-datumMay 15, 1986
CEOMr. Anthony S. Marucci
Anzahl der mitarbeiter186
WertpapierartOrdinary Share
GeschäftsjahresendeMay 15
Addresse53 Frontage Road
StadtHAMPTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl08827
Telefon19084547120
Websitehttps://celldex.com/
BörsenkürzelCLDX
IPO-datumMay 15, 1986
CEOMr. Anthony S. Marucci
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
34.14K
+38.79%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Mr. Herbert J. (Herb) Conrad
Mr. Herbert J. (Herb) Conrad
Independent Director
Independent Director
2.56K
--
Mr. James J. (Jim) Marino
Mr. James J. (Jim) Marino
Independent Director
Independent Director
2.20K
--
Mr. Keith L. Brownlie, CPA
Mr. Keith L. Brownlie, CPA
Independent Director
Independent Director
666.00
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
34.14K
+38.79%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Wellington Management Company, LLP
12.58%
Kynam Capital Management LP
9.79%
BlackRock Institutional Trust Company, N.A.
6.97%
Fidelity Management & Research Company LLC
5.85%
The Vanguard Group, Inc.
5.85%
Other
58.95%
Aktionäre
Aktionäre
Anteil
Wellington Management Company, LLP
12.58%
Kynam Capital Management LP
9.79%
BlackRock Institutional Trust Company, N.A.
6.97%
Fidelity Management & Research Company LLC
5.85%
The Vanguard Group, Inc.
5.85%
Other
58.95%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
45.68%
Hedge Fund
31.15%
Investment Advisor/Hedge Fund
29.65%
Research Firm
3.45%
Venture Capital
2.56%
Bank and Trust
0.33%
Pension Fund
0.31%
Individual Investor
0.27%
Insurance Company
0.04%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
419
75.39M
113.55%
-14.43M
2025Q1
437
75.31M
113.46%
-13.68M
2024Q4
437
75.05M
113.05%
-8.14M
2024Q3
429
73.28M
110.59%
-7.16M
2024Q2
432
71.48M
107.86%
-10.62M
2024Q1
419
71.32M
108.50%
+952.72K
2023Q4
406
62.72M
112.33%
-412.93K
2023Q3
403
52.10M
110.18%
-8.63M
2023Q2
410
51.84M
109.57%
-7.47M
2023Q1
419
51.38M
108.89%
-6.42M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Wellington Management Company, LLP
8.35M
12.58%
-621.68K
-6.93%
Mar 31, 2025
Kynam Capital Management LP
6.50M
9.79%
+1.44M
+28.35%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.62M
6.97%
-29.87K
-0.64%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.89M
5.85%
+441.18K
+12.80%
Mar 31, 2025
The Vanguard Group, Inc.
3.89M
5.85%
+16.44K
+0.42%
Mar 31, 2025
Eventide Asset Management, LLC
3.75M
5.66%
+1.53K
+0.04%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.35M
5.05%
-144.43K
-4.13%
Mar 31, 2025
Commodore Capital LP
3.35M
5.05%
+150.00K
+4.69%
Apr 03, 2025
Bellevue Asset Management AG
3.07M
4.63%
--
--
Mar 31, 2025
State Street Global Advisors (US)
2.81M
4.23%
-428.60K
-13.25%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ALPS Medical Breakthroughs ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
SPDR S&P Biotech ETF
0.37%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
Nuveen ESG Small-Cap ETF
0.11%
Fidelity Fundamental Small-Mid Cap ETF
0.11%
T Rowe Price Small-Mid Cap ETF
0.1%
iShares Russell 2000 Value ETF
0.1%
Avantis US Small Cap Equity ETF
0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.07%
Mehr Anzeigen
ALPS Medical Breakthroughs ETF
Anteil0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.9%
SPDR S&P Biotech ETF
Anteil0.37%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.21%
Nuveen ESG Small-Cap ETF
Anteil0.11%
Fidelity Fundamental Small-Mid Cap ETF
Anteil0.11%
T Rowe Price Small-Mid Cap ETF
Anteil0.1%
iShares Russell 2000 Value ETF
Anteil0.1%
Avantis US Small Cap Equity ETF
Anteil0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
Anteil0.07%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
